RxDoctor Payments Data

Julie Nelson, DO

Family Medicine · Irwin, PANPI 1730325580

Payments from drug & device makers

$614in general payments, 2019–2025

Across 32 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$167
  • Pfizer$91
  • Abbott$60
  • Johnson & Johnson$49
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • AbbVie$47
  • plus $154 from 8 others

What the payments were for

  • Food & beverage$614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$614 in reported general payments places this provider in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$62,990
Medicare patients
217
Services billed
920

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban151$100,279
OzempicSemaglutide97$99,318
XareltoRivaroxaban94$56,442
TrulicityDulaglutide38$41,754
JardianceEmpagliflozin25$28,831
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$28,189
ProliaDenosumab14$24,400
Breo ElliptaFluticasone/Vilanterol33$18,411
RybelsusSemaglutide14$17,843
LinzessLinaclotide19$17,094
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,341
Pantoprazole Sodium267$6,474
TrintellixVortioxetine Hydrobromide14$6,460
Atorvastatin Calcium671$6,318
MyrbetriqMirabegron13$5,865

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$167$117,161111 claims
PfizerEliquis, Abrysvo, Paxlovid$91$107,164189 claims
Johnson & JohnsonXarelto$49$56,44294 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$20$55,94066 claims
Lilly USA, LLCTrulicity$19$41,75438 claims
Boehringer IngelheimJardiance$14$28,83125 claims
AbbVieLinzess, Synthroid$47$18,83287 claims
Astellas Pharma US IncMyrbetriq$21$5,86513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Irwin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →